{"name":"Qurient Co., Ltd.","slug":"qurient-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPb3I0V2dVQXFmcE9MX0VXWlg3YzhBQkYydlpKZjVsSXdtOUM3c2FnVEtZaHZoSjdDUmQ3TnNtaUpyNkVWc29xNDIzRElhRUdJWTJGSGNZSGs1d0J5WVNYb0ptTjRtTmhfNkxId0VmZ285RGFYaVJseFljZlZieUl4THgwUUZqNHZpSFNmV0lOWXpFLXItc3E1WFR3?oc=5","date":"2026-03-25","type":"trial","source":"openPR.com","summary":"Hepatic Tumor Clinical Trial Pipeline Shows Potential with Active Contributions from 75+ Key Companies | DelveInsight - openPR.com","headline":"Hepatic Tumor Clinical Trial Pipeline Shows Potential with Active Contributions from 75+ Key Companies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNeC1xTV9JMmNIcnQ4aHp3NzBVakdyVngxWUZESUx4b2ZRRi1pR3VwVFlxdGVZVEE4dzVDTlptSWhleXMtc0NJdnBvNFMyWXlCak1EMGloXzFhQWFmRm91M3ZfdXlNTHhiQlVxbzNEUmQ5ejdPYXE3djhxZm1aMl95MjFxem1Bbjk3NVZwZVc0ODVOREdNX1RN?oc=5","date":"2026-03-20","type":"trial","source":"openPR.com","summary":"Hepatic Tumor Clinical Trial Landscape Strengthens as 75+ - openPR.com","headline":"Hepatic Tumor Clinical Trial Landscape Strengthens as 75+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPYUM3SDdEZHdFcHV1Y0pVckI2Y0RrVERCYVhEUS1lWUhNdUVObDY0VTFZbjEwM2R4dkt1a3hsTG50ck9ObnlMQXB5M2lkMm1yQ0pTSS12cnVWeG51V0tKU1JLbko2aXZ3M25UOFJGTkxUUWZ0RG0zb19hYmM1NHFucUZueE1POXJtb3QxSlczZmZzWC1LdDcyUHU2S3IyU29VSnJDWW9OZjJPdw?oc=5","date":"2026-03-12","type":"pipeline","source":"Medscape","summary":"Tachyphylaxis in Psoriasis: What’s Really Happening? - Medscape","headline":"Tachyphylaxis in Psoriasis: What’s Really Happening?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNeUZsTVVMVzZ5TWlULVEzTW1PejNkODhMd3RQdFRRNDlLd214UE84ZERwbEprWl9WQWtHQzJhR18xdUYwQndtU3RqRExVUTV3UGpsOGVaR3JDbFl6OF9MNkJnc0Y1SmFJVTBjT1pobkpYVk9zdXZ0VVBScUIzdlFuZ2dXcHlIS2hRWmVFZDlWalEwcG81LTB2anpuVnQ3LVFvNmgzaGU2dklGYVRxOHViQXVoUE1wdHU5VTNyUXhIdUl2c2lxLTJKYnU3eTRYX1dZeE5Ua01RNVllMlptcEpTUVB6cFlKWEtTU1hNX2QxZVMyVTZTVVB4Tm0wOXZ6Z1BoYmhLZlpELUNIV1RNSFl4UVNyeEJmSWREUFlkRElGVUc?oc=5","date":"2026-03-02","type":"regulatory","source":"PR Newswire UK","summary":"Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (202","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxPNTlrMzJLMTUyX3RKRzJWYi1UX1RvSlZ2RUNEd2EtcDJmemhHLUlFZXQxSjcza29rTE9kUFRwRUN2ckdQS0tMcHhfUEN1VDUxeHZMQ1A4NWtqeUYwSFBpM1Y5ZUo3U1NqSk9nM2NtQXBwMDg0R2k3a2U4VTVkSktvR1pxVW8zdS1pQUZ5aExHU3dtY3Y3MTUyVmt2NzVITFBQUktxdHVORlM5WDFTcGZGYkJvM3pNc1ByYTFQT1ZNOUZBYkp6elFBbzNqT3RUQXBNU0FVYWoyemFGRUdUajJjTzlZX2kxX0phc1d2M0xoa1g5TWtvT1N0NVBWY2pZcERNd3N2ck5UV3FWU0MxUWtCbnd3?oc=5","date":"2026-02-16","type":"pipeline","source":"PR Newswire UK","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight - PR Newswire UK","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOcEszejE0MHFfRXZKcDZqd2lLaDNpdEN2SXhhTURiUHIwZW5xci1RTS16S0E0YlN4cVppWXJwaGMtbE9jYU1pN1dNbGVFTG5OMUlPN2pibWNwWExhRE5NQWhzMktpNnMyOUxySEJEUnR5QWJOdHZtT3h6QmdBQVY0OXVQT0NXM3ZoWTlEWHF3RE85TkFzVWJCUDR1UQ?oc=5","date":"2025-09-25","type":"pipeline","source":"Yahoo Finance","summary":"Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC - Yahoo Finance","headline":"Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxPWEZyd1hOQzFxWFdET2NWN3NmaVRsZ09nVXI2R3ZDdTFfQUwwWGlZVXR1NlhncjMzRTBBYWpiejI1bHZHN1pTeTZoVi1uMkZyRVJZcUUtdXpGT3h3b3R2UmN6R1dBSFdRYnBLcjJmUl9kc2JYSkFfOG85cE5HeDFMNkVEenJDSF9HQXA5QTViSkkzLWUzRy1VVzVsdktoVlREOVRta3Y5VTZ1OThhMmhNQ2ExRVBlZUxTTnpOenVsdUNEUzhaUFZJMkxJel96VHVET3Nzamx0aUlTODdTa1luM2lpejVCOHIyLWNhOVE0amVsOXJILVUtbzU0bVNMUmJ6cFhVOXczal9ZTzlSWG5WQkV2a0JKbW1BbjdJZEoyemY?oc=5","date":"2025-01-22","type":"trial","source":"PR Newswire","summary":"Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics S","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1pLXlydnE1cy11OWFhZ01SbW1JSVFnS3MwZDFYSERrQ1M1ZmdSbW5iaHdrbnB6TGNGUy02Wldaa3VZR0g5TzUzUWdLdnVBZDZ2elhJejdMR19wdnoxM3EwSWNXSGNTZW5mSWdKYkFR0gFyQVVfeXFMTTBsVnByUmtHOHZzU1lNTlZ1UDd0TTRmaS1UYUpEOWo2dWdUMGlvZXZlajBnSlhwemRMa0I5aVl0Z2c1TkFpb2xHRHRjVTJ5YjctbmVRdUZYQjdhQ0tMXy1wTmRTWFlPWEx1SE1vcnNqUVpR?oc=5","date":"2025-01-03","type":"regulatory","source":"koreabiomed.com","summary":"Qurient's Adrixetinib receives FDA IND approval for chronic graft-versus-host disease trial - koreabiomed.com","headline":"Qurient's Adrixetinib receives FDA IND approval for chronic graft-versus-host disease trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1wRk55YzhJNlI5azdSTVRiZWxkeHZhX1lHQUNmWTJSTUhaakNQU0FxcXczTnNzVWFsWnNMR050bHIyYUNkR016MFpMV0NPa0FNRUw0a1o5djN6b3UyX210X0Z1dlhLSzBlRkJLVmp30gFyQVVfeXFMTjVxYV9BUG9sVzFSTmFScWpiZ2huQXVONkxwdVRvYWJFcVRJX1V2ekRpdGs3MFdaUU5ZRGhSU2t0Um56ZGdHckx0NS1MV2NnUkdRSzd2ME1kV1lPcDE1bS1uRkM3YlUyRjZRV0JsbmFEV0dB?oc=5","date":"2024-04-15","type":"pipeline","source":"koreabiomed.com","summary":"DongKoo Bio & Pharma becomes Qurient's largest shareholder through strategic investment - koreabiomed.com","headline":"DongKoo Bio & Pharma becomes Qurient's largest shareholder through strategic investment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBXUmhHSU9kdHRBMEZ3Y01vUEl6VURZU3V1Vi05S1VBemdmbHotbGZTTWZ6d3ZYYlNsRWVIejdhNUJjbzQyMElJcDljVlQ2UGxlNXdxNTlHMktyTzZPZ1RyYzEyeFhSeW43MlJnUk5n?oc=5","date":"2023-08-14","type":"pipeline","source":"KED Global","summary":"S.Korea's Qurient, US National Cancer Institute to develop anti-cancer drug - KED Global","headline":"S.Korea's Qurient, US National Cancer Institute to develop anti-cancer drug","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}